Clinical Trials
27 trialsNCT03632941 2026-06-04
A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
Duke University
Phase 2 Terminated
NCT06188208 2026-03-30
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
Phase 1 Terminated
NCT05204290 2026-03-24
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
Wake Forest University Health Sciences
Phase EARLY_PHASE1 Terminated
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT04157517 2026-01-29
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT04009681 2025-12-15
HAMMER
Synthorx, Inc, a Sanofi company
Phase 1/2 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT04717375 2025-08-07
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Sanofi
Phase 1/2 Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04830124 2025-06-10
ARTISTRY-6
Mural Oncology, Inc
Phase 2 Terminated
NCT03948763 2025-01-28
V941-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02972034 2024-11-21
MK-8353-013
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03799003 2024-11-01
A Study of ASP1951 in Subjects With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Terminated
NCT04128696 2024-07-10
INDUCE-3
GlaxoSmithKline
Phase 3 Terminated
NCT03416335 2024-05-30
A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile
Sumitomo Pharma America, Inc.
Phase 1/2 Terminated
NCT03709706 2024-02-23
Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
GlaxoSmithKline
Phase 1/2 Terminated
NCT05357898 2024-02-23
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
SQZ Biotechnologies
Phase 1/2 Terminated
NCT04348916 2023-06-08
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
Phase 1 Terminated
NCT03637803 2023-06-01
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
4D pharma plc
Phase 1/2 Terminated
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT03168438 2022-01-11
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
GlaxoSmithKline
Phase 1 Terminated
NCT04274907 2021-02-11
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
AbbVie
Phase 1 Terminated
NCT02346955 2020-08-27
MK-6018-001
KitovPharma
Phase 1 Terminated
NCT03099161 2019-06-05
MK-3814A-062
Merck Sharp & Dohme LLC
Phase 1 Terminated